{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:10:04Z","timestamp":1751947804670,"version":"3.41.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00642-8","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:38:01Z","timestamp":1751895481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile"],"prefix":"10.1186","volume":"23","author":[{"given":"Tom\u00e1s","family":"Abbot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-0219","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Armijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Rojas","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s Giglio","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-9512","authenticated-orcid":false,"given":"Manuel","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"18","key":"642_CR1","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370\u20135.","journal-title":"JAMA"},{"key":"642_CR2","doi-asserted-by":"crossref","unstructured":"Lane DA, Skj\u00f8th F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Association. 2017;6(5).","DOI":"10.1161\/JAHA.116.005155"},{"issue":"9","key":"642_CR3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cjca.2019.05.019","volume":"35","author":"C Gallagher","year":"2019","unstructured":"Gallagher C, Hendriks JM, Middeldorp ME, Elliott AD, Lau DH, Sanders P. Reducing the burden of atrial fibrillation cost: is integrated care the answer?? Can J Cardiol. 2019;35(9):1094\u20136.","journal-title":"Can J Cardiol"},{"issue":"1","key":"642_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12913-017-2652-y","volume":"17","author":"SP Johnsen","year":"2017","unstructured":"Johnsen SP, Dalby LW, T\u00e4ckstr\u00f6m T, Olsen J, Fraschke A. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017;17(1):714.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"642_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/cvr\/cvab170","volume":"117","author":"S Nattel","year":"2021","unstructured":"Nattel S, Lip GYH, Filgueiras-Rama D, Dobrev D. Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. Cardiovascular Res. 2021;117(7):1609\u201311.","journal-title":"Cardiovascular Res"},{"key":"642_CR6","doi-asserted-by":"crossref","unstructured":"Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011;13(10):1375-85.","DOI":"10.1093\/europace\/eur194"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IJGM.S62819","volume":"7","author":"L Cubillos","year":"2014","unstructured":"Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014;7:441\u20138.","journal-title":"Int J Gen Med"},{"issue":"1","key":"642_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.recesp.2019.02.003","volume":"73","author":"M Anguita S\u00e1nchez","year":"2020","unstructured":"Anguita S\u00e1nchez M, Bertomeu Mart\u00ednez V, Ruiz Ortiz M, Cequier Fillat \u00c1, Rold\u00e1n Rabad\u00e1n I, Mu\u00f1iz Garc\u00eda J, et al. Anticoagulantes orales Directos Frente a antagonistas de La vitamina K En Pacientes Del \u00abmundo real\u00bb Con fibrilaci\u00f3n auricular no valvular. Estudio FANTASIIA. Rev Esp Cardiol. 2020;73(1):14\u201320.","journal-title":"Rev Esp Cardiol"},{"issue":"5","key":"642_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"issue":"12","key":"642_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"6","key":"642_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran reversal. N Engl J Med. 2015;373(6):511\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"642_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J van Ryn","year":"2010","unstructured":"van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116\u201327.","journal-title":"Thromb Haemost"},{"issue":"10105","key":"642_CR13","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(17)31072-3","volume":"390","author":"P Kirchhof","year":"2017","unstructured":"Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet (London England). 2017;390(10105):1873\u201387.","journal-title":"Lancet (London England)"},{"issue":"5","key":"642_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4067\/s0034-98872021000500724","volume":"149","author":"B Leal","year":"2021","unstructured":"Leal B, Torres H, Roco \u00c1, Rom\u00e1n R, Rojo M, Nieto E, et al. Impacto de La Atenci\u00f3n farmac\u00e9utica En La Calidad Del Tratamiento Con Acenocumarol En Pacientes Con fibrilaci\u00f3n auricular. Revista M\u00e9dica De Chile. 2021;149(5):724\u201332.","journal-title":"Revista M\u00e9dica De Chile"},{"issue":"5","key":"642_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/clc.23176","volume":"42","author":"C Jerjes-Sanchez","year":"2019","unstructured":"Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Allu J, Illingworth L, et al. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: insights from the GARFIELD-AF registry. Clin Cardiol. 2019;42(5):553\u201360.","journal-title":"Clin Cardiol"},{"issue":"6","key":"642_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ahj.2009.03.022","volume":"157","author":"SV Sorensen","year":"2009","unstructured":"Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus real-world stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064\u201373.","journal-title":"Am Heart J"},{"issue":"5","key":"642_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1160\/TH11-02-0089","volume":"105","author":"SV Sorensen","year":"2011","unstructured":"Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908\u201319.","journal-title":"Thromb Haemost"},{"issue":"3","key":"642_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1345\/aph.1E169","volume":"39","author":"J Menzin","year":"2005","unstructured":"Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Annals Pharmacotherapy. 2005;39(3):446\u201351.","journal-title":"Annals Pharmacotherapy"},{"key":"642_CR19","unstructured":"Departamento de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias y Salud Basada en Evidencia. Gu\u00eda Metodol\u00f3gica para la evaluaci\u00f3n econ\u00f3mica de intervenciones en salud en Chile Santiago de Chile: Ministerio de Salud; 2013 [Available from: https:\/\/etesa-sbe.minsal.cl\/unidad-de-evaluaciones-economicas\/publicaciones-unidad-de-evaluaciones-economicas\/"},{"key":"642_CR20","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. 2017;359:j5058.","DOI":"10.1136\/bmj.j5058"},{"issue":"19","key":"642_CR21","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690\u20131.","journal-title":"JAMA"},{"key":"642_CR22","unstructured":"MINisterio de Salud de Chile. ENS - Encuesta Nacional de Salud: Ministerio de Salud de Chile. 2017 [Available from: http:\/\/epi.minsal.cl\/encuesta-ens\/"},{"issue":"16","key":"642_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","volume":"156","author":"BF Gage","year":"1996","unstructured":"Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156(16):1829\u201336.","journal-title":"Arch Intern Med"},{"issue":"10","key":"642_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2165\/00019053-200624100-00009","volume":"24","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. PharmacoEconomics. 2006;24(10):1021\u201333.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"642_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the united Kingdom. Med Decis Making: Int J Soc Med Decis Mak. 2011;31(6):800\u20134.","journal-title":"Med Decis Making: Int J Soc Med Decis Mak"},{"key":"642_CR26","unstructured":"NICE, TA249]: National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation [ 2012 [Available from: https:\/\/www.nice.org.uk\/guidance\/ta249\/chapter\/4-Consideration-of-the-evidence"},{"key":"642_CR27","unstructured":"Compras CENABAST. [Internet]. Central Nacional de Abastecimiento. 2021. Available from: https:\/\/www.cenabast.cl\/compras-cenabast\/"},{"key":"642_CR28","volume-title":"Estudio final Del estudio de verificaci\u00f3n Del Costo Esperado individual Promedio Por beneficiario Del Conjunto priorizado de problemas de Salud Con Garant\u00edas Expl\u00edcitas 2018","author":"Ministerio de Salud de Chile","year":"2019","unstructured":"Ministerio de Salud de Chile. Estudio final Del estudio de verificaci\u00f3n Del Costo Esperado individual Promedio Por beneficiario Del Conjunto priorizado de problemas de Salud Con Garant\u00edas Expl\u00edcitas 2018. Santiago de Chile: Ministerio de Salud de Chile; 2019."},{"key":"642_CR29","unstructured":"FONASA. Aranceles Santiago de Chile: Fondo Nacional de Salud. 2021 [Available from: https:\/\/www.fonasa.cl\/sites\/fonasa\/prestadores\/modalidad-atencion-institucional"},{"key":"642_CR30","doi-asserted-by":"crossref","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oup Oxford; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"3","key":"642_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1227\/NEU.0b013e318261749b","volume":"71","author":"F Siddiq","year":"2012","unstructured":"Siddiq F, Chaudhry SA, Tummala RP, Suri MF, Qureshi AI. Factors and outcomes associated with early and delayed aneurysm treatment in subarachnoid hemorrhage patients in the united States. Neurosurgery. 2012;71(3):670\u20137. discussion 7\u20138.","journal-title":"Neurosurgery"},{"issue":"5","key":"642_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.thromres.2014.02.024","volume":"133","author":"CH Chang","year":"2014","unstructured":"Chang CH, Yang YH, Chen JH, Lin LJ. Cost-effectiveness of Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Thromb Res. 2014;133(5):782\u20139.","journal-title":"Thromb Res"},{"issue":"7","key":"642_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","volume":"98","author":"AR Kansal","year":"2012","unstructured":"Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of Dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573\u20138.","journal-title":"Heart"},{"issue":"1","key":"642_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40261-013-0144-3","volume":"34","author":"C Rognoni","year":"2014","unstructured":"Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and Rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34(1):9\u201317.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"642_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3111\/13696998.2013.766200","volume":"16","author":"H Wouters","year":"2013","unstructured":"Wouters H, Thijs V, Annemans L. Cost-effectiveness of Dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. 2013;16(3):407\u201314.","journal-title":"J Med Econ"},{"issue":"1","key":"642_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.clinthera.2019.11.011","volume":"42","author":"SJ Dong","year":"2020","unstructured":"Dong SJ, Wu B, Zhai SD, Zhang YJ, Chu YB, Gupta P, et al. Cost-effectiveness of Dabigatran compared with Rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China. Clin Ther. 2020;42(1):144\u2013e561.","journal-title":"Clin Ther"},{"issue":"9","key":"642_CR37","doi-asserted-by":"publisher","first-page":"e0222658","DOI":"10.1371\/journal.pone.0222658","volume":"14","author":"LA de Jong","year":"2019","unstructured":"de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, et al. Cost-effectiveness of Apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE. 2019;14(9):e0222658.","journal-title":"PLoS ONE"},{"key":"642_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/CEOR.S317078","volume":"13","author":"T Hallinen","year":"2021","unstructured":"Hallinen T, Soini E, Asseburg C, Linna M, Eloranta P, Sintonen S, et al. Cost-Effectiveness of Apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with Non-Valvular atrial fibrillation. ClinicoEconomics Outcomes Research: CEOR. 2021;13:745\u201355.","journal-title":"ClinicoEconomics Outcomes Research: CEOR"},{"issue":"3","key":"642_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40261-021-01002-z","volume":"41","author":"V Lorenzoni","year":"2021","unstructured":"Lorenzoni V, Pirri S, Turchetti G. Cost-Effectiveness of direct Non-Vitamin K oral anticoagulants versus vitamin K antagonists for the management of patients with Non-Valvular atrial fibrillation based on available Real-World evidence: the Italian National health system perspective. Clin Drug Investig. 2021;41(3):255\u201367.","journal-title":"Clin Drug Investig"},{"key":"642_CR40","doi-asserted-by":"crossref","unstructured":"Celeste MG, De Marco F, Fresco C, Musumeci G, Ravasio R. Budget impact analysis of Dabigatran compared with Rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation. Farmeconomia Health Econ Therapeutic Pathways. 2017;18(1).","DOI":"10.7175\/fe.v18i1.1327"},{"issue":"5","key":"642_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/13696998.2016.1273229","volume":"20","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr., Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, et al. Healthcare resource utilization in patients receiving Idarucizumab for reversal of Dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD\u2122 study. J Med Econ. 2017;20(5):435\u201342.","journal-title":"J Med Econ"},{"issue":"12","key":"642_CR42","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.recesp.2015.07.028","volume":"68","author":"V Barrios","year":"2015","unstructured":"Barrios V, Escobar C, Prieto L, Lobos JM, Polo J, Vargas D. Control of anticoagulation with warfarin or acenocoumarol in spain. Do they differ?? Revista Esp De Cardiologia (English ed). 2015;68(12):1181\u20132.","journal-title":"Revista Esp De Cardiologia (English ed)"},{"key":"642_CR43","doi-asserted-by":"crossref","unstructured":"Dalmau Llorca MR, Aguilar Mart\u00edn C, Carrasco-Querol N, Hern\u00e1ndez Rojas Z, Forcadell Drago E, Rodr\u00edguez Cumplido D et al. Anticoagulation control with acenocoumarol or warfarin in Non-Valvular atrial fibrillation in primary care (Fantas-TIC Study). Int J Environ Res Public Health. 2021;18(11).","DOI":"10.3390\/ijerph18115700"},{"key":"642_CR44","doi-asserted-by":"crossref","unstructured":"Romero LR, Vargas MP, Letelier AV. Warfarina versus Acenocumarol En Alcanzar niveles terap\u00e9uticos En Una Poblaci\u00f3n ambulatoria. Revista Chil De Cardiolog\u00eda. 2009;28(4).","DOI":"10.4067\/S0718-85602009000300006"},{"issue":"8","key":"642_CR45","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.recesp.2014.08.010","volume":"68","author":"G Bar\u00f3n Esquivias","year":"2015","unstructured":"Bar\u00f3n Esquivias G, Escolar Albaladejo G, Zamorano JL, Beteg\u00f3n Nicol\u00e1s L, Canal Fontcuberta C, de Salas-Cansado M, et al. Cost-effectiveness analysis comparing Apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Revista Esp De Cardiologia (English ed). 2015;68(8):680\u201390.","journal-title":"Revista Esp De Cardiologia (English ed)"},{"issue":"5","key":"642_CR46","first-page":"1425","volume":"26","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Poli D, Antonucci E, Cammisotto V, Testa S, Pignatelli P, et al. Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: insights from the nationwide. PLECTRUM Study. 2021;26(5):1425.","journal-title":"PLECTRUM Study"},{"key":"642_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vhri.2015.02.003","volume":"8","author":"C de Pepe Ribeiro","year":"2015","unstructured":"de Pepe Ribeiro C, Bolzachini Santoni N, Gomes de Melo T, Jansen de Oliveira Figueiredo M, da Costa Darrieux FC, Soares Piegas L, et al. Cost-Effectiveness and Cost-Utility analyses of Dabigatran compared with warfarin in patients with nonvalvular atrial fibrillation and risk factors for stroke and systemic embolism within Brazilian private and public health care systems perspectives. Value Health Reg Issues. 2015;8:36\u201342.","journal-title":"Value Health Reg Issues"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00642-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:38:04Z","timestamp":1751895484000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00642-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00642-8","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}